Hardy Reed LLC Reduces Stake in Agilent Technologies, Inc. $A

Hardy Reed LLC lessened its holdings in Agilent Technologies, Inc. (NYSE:A) by 12.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,750 shares of the medical research company’s stock after selling 400 shares during the quarter. Hardy Reed LLC’s holdings in Agilent Technologies were worth $325,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Agilent Technologies by 13.5% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after purchasing an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock valued at $3,606,000 after buying an additional 2,371 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock valued at $1,563,000 after buying an additional 3,040 shares during the period. D.A. Davidson & CO. boosted its stake in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after buying an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. lifted its holdings in Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock valued at $89,870,000 after acquiring an additional 54,302 shares during the period.

Agilent Technologies Stock Performance

NYSE A opened at $141.64 on Tuesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock’s 50 day simple moving average is $123.24 and its 200-day simple moving average is $116.49. The company has a market cap of $40.15 billion, a PE ratio of 33.25, a price-to-earnings-growth ratio of 4.62 and a beta of 1.26. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm’s revenue was up 10.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies’s dividend payout ratio is currently 23.24%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday. Wells Fargo & Company upped their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, September 15th. Barclays increased their target price on shares of Agilent Technologies from $125.00 to $150.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Agilent Technologies in a research note on Saturday, September 27th. Six investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $142.17.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.